Loading stock data…
CING
$5.37+0.22 (+4.27%)
Market ClosedLast close May 1
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cingulate Inc. in the Healthcare sector is trading at $5.37. The stock is currently 55% below its 52-week high of $11.89, remaining 8.9% above its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why CING maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.37
Potential Upside
5%
Whystock Fair Value$5.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$68.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-845.20%
Volume
Today's trading volume
316,807
Recent News
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the recent acceptance of an NDA for its lead ADHD candidate, CTx-1301. The company also announced a strengthened intellectual property portfolio, including a […]
Cingulate price target lowered to $16 from $17 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management to discuss Q3 results. The company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, though the firm is adjusting its model on expectation that Cingulate may choose to raise capital during the next 6 to 12 months, the analyst tells investors in a research note.TipRanks